Real‐World Evidence of Dupilumab's Efficacy in Reducing Autoantibodies to Bullous Pemphigoid Antigens

Use of AI Statement: AI was not used in the generation of this manuscript. Authors Kateryna Karpoff, Anya Patel, and Georgina Erfe have no conflicts of interest to declare. Dr. Mark Lebwohl is an employee of Mount Sinai and receives research funds from: Abbvie, Arcutis, Avotres, Boehringer Ingelheim, Cara therapeutics, Clexio, Dermavant Sciences, Eli Lilly, Incyte, Inozyme, Johnson & Johnson, Oruka, Pfizer, Sanofi-Regeneron, and UCB, and is a consultant for Added Health, Aikium, Almirall, AltruBio Inc., Alumis, Amgen, Apogee, Arcutis Inc., AstraZeneca, Atomwise, Avotres Therapeutics, Boehringer-Ingelheim, Bristol-Myers Squibb, Castle Biosciences, Celltrion, Corevitas, Dermavant Sciences, Dermsquared, Evommune Inc., Facilitation of International Dermatology Education, Forte biosciences, Galderma, Genentech, Incyte, LEO Pharma, Mayne Pharmaceuticals, Meiji Seika Pharma, Mindera, Mirium Pharmaceuticals, Moonlake, Oruka, Pfizer, Sanofi-Regeneron, Revolo, Seanergy, Strata, Sunpharma, Takeda, Trevi, and Verrica. Dr. Emma Guttman-Yassky is an employee of Mount Sinai and has received research grants (paid to the institution) from Regeneron, Sanofi, Eli Lilly, Galderma, Leo Pharma, Pfizer, Amgen, GSK, Incyte, Sanofi, Bristol Meyers Squibb, Arcutis, AnaptysBio, Inmagene, Abbvie, Xencor, Q32 Bio, Opsidio, Apollo Therapeutics, Aclaris Therapeutics, Concerto Biosciences, Alumis, Apogee, Enveda. Nektar. Dr. Guttman-Yassky has received honoraria from Abbvie, Aclaris Therapeutics, Almirall, Alumis, Amgen, AnaptysBio, Apogee Therapeutics, Apollo Therapeutics, Arcutis, Artax Biopharma, Astria, Bambusa, Biolojic Design, Boerhinger-Ingelhiem, Bristol Meyers Squibb, Celldex, Connect Biopharm, Coty, Cue Biopharma, CytoReason, DBV, Dualitas Therapeutics, Electra Therapeutic, Eli Lilly, EMD Serono, Enveda Biosciences, Evommune, Galderma, Generate Biomedicines, GSK, Incyte, Inmagene, Janssen Biotech, Jasper Therapeutics, Kymera Therapeutics, Kyowa Kirin, Leo Pharma, Matchpoint Therapeutics, Merck, Navigator Medicines, Nektar Therapeutics, NUMAB Therapeutics, Pfizer, Proteologix, Priovant Therapeutics, RAPT, RayThera, Recludix Pharma, Regeneron, Sanofi, SATO, Sitryx, Schrödinger, SPARC, Takeda, Teva, Third Arc Bio (TAB), TRex Bio, Triveni Bio, UCB, Ventyx, Veradermics, VRG Therapeutics. The data that support the findings of this study are available from the corresponding author upon reasonable request.